Skip to main content
Premium Trial:

Request an Annual Quote

Firefly Bio Raises $775K, Eyeing $1.5M

NEW YORK (GenomeWeb) – Firefly BioWorks said in a document filed with the US Securities and Exchange Commission that it has raised $775,000 toward a targeted amount of $1.5 million.

The names of the investors or how the funds would be used were not disclosed. A spokesperson for Cambridge, Mass.-based miRNA assay firm declined to comment.

Firefly's portfolio includes the multiplexed Firefly Cellular microRNA Assay, which allows up to 68 small RNA targets of interest to be analyzed simultaneously. The assay is based on hydrogel particles and can be completed in approximately four hours, according to Firefly's website.

In the fall, Firefly signed a deal with EMD Millipore, a division of Germany's Merck KGaA, for the global distribution of Firefly's SmartRNAplex miRNA profiling assay.

The firm also has been developing the Firefly Circulating microRNA Assay, which detects up to 68 miRNA targets per sample in a 96-well format. The assay combines particle-based multiplexing with single-step RT-PCR signal amplification using universal primers. According to Firefly, the assay will be launching this summer.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.